藥物臨床試驗是評估新藥安全性、有效性，推動醫(yī)學(xué)進(jìn)步，提供創(chuàng)新治療方法不可或缺的關(guān)鍵步驟；在中國老齡化人口增加的趨勢下，提升臨床試驗老年受試者的依從性至關(guān)重要。為確保研究結(jié)果更具代表性和適用性，建議采取以下措施：首先，制定個性化支持計劃和多元化的依從性監(jiān)測方法；其次，根據(jù)老年人的生活方式和需求，調(diào)整試驗設(shè)計以提升參與的舒適度和便捷性；此外，建立社會支持系統(tǒng)以提供更廣泛的支持；最后，通過加強(qiáng)研究團(tuán)隊的培訓(xùn)，提高對老年患者的關(guān)懷水平，激發(fā)其積極性和合作度。這些舉措有助于減小藥物臨床試驗的選擇性和信息偏倚，為改善醫(yī)療護(hù)理和推動醫(yī)學(xué)科學(xué)的發(fā)展提供可靠的研究基礎(chǔ)。通過科學(xué)、倫理和規(guī)范的試驗設(shè)計和實施，可以更好地評估藥物的效果，為患者提供更好的醫(yī)療選擇。

Clinical drug trials are crucial steps in assessing the safety and efficacy of new medications, driving medical advancements, and providing essential innovation in treatment methods. With the increasing trend of aging populations in China, enhancing the compliance of elderly participants in clinical trials is of paramount importance. To ensure more representative and applicable research outcomes, the following measures are recommended:firstly, establish personalized support plans and diverse compliance monitoring methods. Secondly, adjust trial designs based on the lifestyles and needs of older individuals to enhance participation comfort and convenience. Furthermore, establish social support systems to provide broader assistance. Finally, strengthen the training of research teams to elevate the level of care for elderly patients and stimulate their enthusiasm and cooperation. These initiatives contribute to reducing selection and information biases, laying a reliable research foundation for improving healthcare and driving advancements in medical science. Through scientifically, ethically, and rigorously designed and implemented trials, a better assessment of the effectiveness of medications can be achieved, offering improved medical choices for patients.

R969.4

上海市中醫(yī)藥“三年行動計劃”項目［ZY（2021-2023）-0211］；上海市“科技創(chuàng)新行動計劃”生物醫(yī)藥科技支撐專項（20S21902100）；上海市教委協(xié)同創(chuàng)新中心：中西醫(yī)結(jié)合-中成藥臨床評價平臺項目（A1-U21-205-0103）；上海市慢性筋骨病臨床醫(yī)學(xué)研究中心項目（20MC1920600）；上海市科委2022年度第三批應(yīng)急科技攻關(guān)項目（22YJ1900505）；上海市申康中心示范性研究型病房建設(shè)項目（SHDC2022CRW010）；上海市申康中心醫(yī)企融合創(chuàng)新協(xié)同專項（SHDC2022CRT018）